153 related articles for article (PubMed ID: 37158824)
21. Impact of tumor location and pathological discordance on survival of children with midline high-grade gliomas treated on Children's Cancer Group high-grade glioma study CCG-945.
Eisenstat DD; Pollack IF; Demers A; Sapp MV; Lambert P; Weisfeld-Adams JD; Burger PC; Gilles F; Davis RL; Packer R; Boyett JM; Finlay JL
J Neurooncol; 2015 Feb; 121(3):573-81. PubMed ID: 25431150
[TBL] [Abstract][Full Text] [Related]
22. Prognostic biomarker SGSM1 and its correlation with immune infiltration in gliomas.
Li J; Wang J; Ding Y; Zhao J; Wang W
BMC Cancer; 2022 Apr; 22(1):466. PubMed ID: 35484511
[TBL] [Abstract][Full Text] [Related]
23. Elevated expression of mitochondrial transcription elongation factor (TEFM) predicts poor prognosis in low grade glioma-an analysis of the Cancer Genome Atlas (TCGA) dataset.
Li S; Wang W; Zi J; Sun M; Mei W; Yang N; Zhang R; Yu M; Xiong W
Transl Cancer Res; 2020 May; 9(5):3610-3622. PubMed ID: 35117724
[TBL] [Abstract][Full Text] [Related]
24. A four-protein expression prognostic signature predicts clinical outcome of lower-grade glioma.
Patil V; Mahalingam K
Gene; 2018 Dec; 679():57-64. PubMed ID: 30077762
[TBL] [Abstract][Full Text] [Related]
25. CKS2 (CDC28 protein kinase regulatory subunit 2) is a prognostic biomarker in lower grade glioma: a study based on bioinformatic analysis and immunohistochemistry.
Hu M; Li Z; Qiu J; Zhang R; Feng J; Hu G; Ren J
Bioengineered; 2021 Dec; 12(1):5996-6009. PubMed ID: 34494924
[TBL] [Abstract][Full Text] [Related]
26. Study on the Prognostic Values of Dynactin Genes in Low-Grade Glioma.
Su X; Li H; Chen S; Qin C
Technol Cancer Res Treat; 2021; 20():15330338211010143. PubMed ID: 33896271
[TBL] [Abstract][Full Text] [Related]
27. Expression of FAS-L Differs from Primary to Relapsed Low-grade Gliomas and Predicts Progression-free Survival.
Werner JM; Kuhl S; Stavrinou P; Röhn G; Krischek B; Blau T; Goldbrunner R; Timmer M
Anticancer Res; 2017 Dec; 37(12):6639-6648. PubMed ID: 29187439
[TBL] [Abstract][Full Text] [Related]
28. Amide proton transfer imaging might predict survival and IDH mutation status in high-grade glioma.
Joo B; Han K; Ahn SS; Choi YS; Chang JH; Kang SG; Kim SH; Zhou J; Lee SK
Eur Radiol; 2019 Dec; 29(12):6643-6652. PubMed ID: 31175415
[TBL] [Abstract][Full Text] [Related]
29. IDH1/2 mutation status combined with Ki-67 labeling index defines distinct prognostic groups in glioma.
Zeng A; Hu Q; Liu Y; Wang Z; Cui X; Li R; Yan W; You Y
Oncotarget; 2015 Oct; 6(30):30232-8. PubMed ID: 26338964
[TBL] [Abstract][Full Text] [Related]
30. Correlation between ITGB2 expression and clinical characterization of glioma and the prognostic significance of its methylation in low-grade glioma(LGG).
Liu H; Wang J; Luo T; Zhen Z; Liu L; Zheng Y; Zhang C; Hu X
Front Endocrinol (Lausanne); 2022; 13():1106120. PubMed ID: 36714574
[TBL] [Abstract][Full Text] [Related]
31. Integrative Analysis of Neuregulin Family Members-Related Tumor Microenvironment for Predicting the Prognosis in Gliomas.
Zhao WJ; Ou GY; Lin WW
Front Immunol; 2021; 12():682415. PubMed ID: 34054873
[TBL] [Abstract][Full Text] [Related]
32. The Change of Soluble Programmed Cell Death-Ligand 1 in Glioma Patients Receiving Radiotherapy and Its Impact on Clinical Outcomes.
Ding XC; Wang LL; Zhu YF; Li YD; Nie SL; Yang J; Liang H; Weichselbaum RR; Yu JM; Hu M
Front Immunol; 2020; 11():580335. PubMed ID: 33224142
[TBL] [Abstract][Full Text] [Related]
33. Overexpression of ZEB1 and YAP1 is related to poor prognosis in patients with gliomas with different IDH1 status.
Miao N; Wang ZQ; Zhang N; Ma ZP; Su LP; Zhai YY; Hu YR; Sang W; Zhang W
Int J Clin Exp Pathol; 2023; 16(7):138-149. PubMed ID: 37559682
[TBL] [Abstract][Full Text] [Related]
34. In vitro neurosphere formation correlates with poor survival in glioma.
C Jayakrishnan P; H Venkat E; M Ramachandran G; K Kesavapisharady K; N Nair S; Bharathan B; Radhakrishnan N; Gopala S
IUBMB Life; 2019 Feb; 71(2):244-253. PubMed ID: 30393962
[TBL] [Abstract][Full Text] [Related]
35. HLA-E expression in diffuse glioma: relationship with clinicopathological features and patient survival.
Wu Z; Liang J; Wang Z; Li A; Fan X; Jiang T
BMC Neurol; 2020 Feb; 20(1):59. PubMed ID: 32066399
[TBL] [Abstract][Full Text] [Related]
36. Elevated expression of macrophage migration inhibitory factor correlates with tumor recurrence and poor prognosis of patients with gliomas.
Wang XB; Tian XY; Li Y; Li B; Li Z
J Neurooncol; 2012 Jan; 106(1):43-51. PubMed ID: 21725855
[TBL] [Abstract][Full Text] [Related]
37. A nuclear transport-related gene signature combined with IDH mutation and 1p/19q codeletion better predicts the prognosis of glioma patients.
Zhu Z; Lan Y; Wang L; Ge J; Wang J; Liu F; He Z; Zhang H; Luo M; Lin D; Tan Y; Xu Y; Luo T
BMC Cancer; 2020 Nov; 20(1):1072. PubMed ID: 33167941
[TBL] [Abstract][Full Text] [Related]
38. 3D-ASL perfusion correlates with VEGF expression and overall survival in glioma patients: Comparison of quantitative perfusion and pathology on accurate spatial location-matched basis.
Pang H; Dang X; Ren Y; Zhuang D; Qiu T; Chen H; Zhang J; Ma N; Li G; Zhang J; Wu J; Feng X
J Magn Reson Imaging; 2019 Jul; 50(1):209-220. PubMed ID: 30652410
[TBL] [Abstract][Full Text] [Related]
39. IL-13 receptor α2 stimulates human glioma cell growth and metastasis through the Src/PI3K/Akt/mTOR signaling pathway.
Tu M; Wange W; Cai L; Zhu P; Gao Z; Zheng W
Tumour Biol; 2016 Nov; 37(11):14701-14709. PubMed ID: 27623944
[TBL] [Abstract][Full Text] [Related]
40. [Nuclear and cytoplasmic expressions of survivin in glioma and their prognostic value].
Pan Y; Hu WH; Xie D; Wu QL; Liu YH; Xiang J; Wu HX
Zhonghua Yi Xue Za Zhi; 2007 Jan; 87(5):325-9. PubMed ID: 17456361
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
